Literature DB >> 18602356

Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.

J P Gisbert1, A G McNicholl.   

Abstract

Faecal calprotectin has been proposed as a non-invasive surrogate marker of intestinal inflammation in inflammatory bowel disease. Close correlation between faecal calprotectin concentration and faecal leukocyte excretion quantified with (111)indium has been described. This faecal marker can be detected using simple and cheap techniques. Faecal calprotectin has a good diagnostic precision for separating organic and functional intestinal diseases. However, the specificity for the diagnosis of inflammatory bowel disease is lower than desirable, as several diseases other than inflammatory bowel disease -- specially colorectal neoplasia and gastrointestinal infection -- can also increase faecal calprotectin. High concentration of calprotectin in faeces is a strong argument to carry out a colonoscopy in order to rule out the presence of inflammatory bowel disease or other organic pathologies. Parallelism between faecal calprotectin levels and inflammatory bowel disease activity has been confirmed, although this faecal marker appears to better reflect the disease activity in ulcerative colitis than in Crohn's disease. Faecal calprotectin's capacity to predict inflammatory bowel diseases relapse is promising. It has been suggested that, in inflammatory bowel disease patients receiving treatment, a normalization or decrease in faecal calprotectin concentrations is an accurate indicator of endoscopic healing. Greater faecal calprotectin concentration has been shown in asymptomatic first-degree relatives of patients with inflammatory bowel disease, suggesting that there is a high prevalence of subclinical intestinal inflammation in them.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602356     DOI: 10.1016/j.dld.2008.05.008

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  70 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

Review 2.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury.

Authors:  Frank Heller; Sandra Frischmann; Maria Grünbaum; Walter Zidek; Timm H Westhoff
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

4.  Soluble ST2: a new and promising activity marker in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía E Núñez; Caroll J Beltrán; Enzo Candia; Cristóbal Suazo; Manuel Alvarez-Lobos; María-Julieta González; Marcela A Hermoso; Rodrigo Quera
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

5.  Fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

Authors:  Gert Van Assche
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-06

6.  Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Authors:  Frank Serge Lehmann; Francesca Trapani; Ida Fueglistaler; Luigi Maria Terracciano; Markus von Flüe; Gieri Cathomas; Andreas Zettl; Pascal Benkert; Daniel Oertli; Christoph Beglinger
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

7.  Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Authors:  Jernej Dolinšek; Petra Rižnik; Larisa Sabath; Dušanka Mičetić-Turk
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

8.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

9.  Intestinal schistosomiasis in mothers and young children in Uganda: investigation of field-applicable markers of bowel morbidity.

Authors:  Martha Betson; Jose Carlos Sousa-Figueiredo; Candia Rowell; Narcis B Kabatereine; J Russell Stothard
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

10.  Fecal calprotectin excretion in preterm infants during the neonatal period.

Authors:  Carole Rougé; Marie-José Butel; Hugues Piloquet; Laurent Ferraris; Arnaud Legrand; Michel Vodovar; Marcel Voyer; Marie-France de la Cochetière; Dominique Darmaun; Jean-Christophe Rozé
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.